Logo
Bg pattern

MOMETASONE MEDE 0.1% CUTANEOUS SOLUTION

Prescription review online

Prescription review online

A doctor will review your case and decide whether a prescription is medically appropriate.

Talk to a doctor about this medicine

Talk to a doctor about this medicine

Discuss your symptoms and possible next steps in a quick online consultation.

This page is for general information. Consult a doctor for personal advice. Call emergency services if symptoms are severe.
About the medicine

How to use MOMETASONE MEDE 0.1% CUTANEOUS SOLUTION

Translated with AI

This page provides general information and does not replace a doctor’s consultation. Always consult a doctor before taking any medication. Seek urgent medical care if symptoms are severe.

Show original

Contents of the leaflet

  1. Introduction
  2. What Mometasona Mede is and what it is used for
  3. What you need to know before starting to use Mometasona Mede
  4. How to use Mometasona Mede
  5. Possible side effects
  6. Storage of Mometasona Mede
  7. Package contents and additional information

Introduction

Leaflet: information for the user

Mometasona Mede1 mg/g cutaneous solution EFG

mometasone furoate

Read the entire leaflet carefully before starting to use the medicine, as it contains important information for you.

  • Keep this leaflet, as you may need to read it again.
  • If you have any doubts, consult your doctor or pharmacist.
  • This medicine has been prescribed to you personally and should not be given to others, even if they have the same symptoms, as it may harm them.
  • If you experience side effects, consult your doctor or pharmacist, even if they are side effects not listed in this leaflet. See section 4.

Contents of the leaflet:

  1. What Mometasona Mede is and what it is used for
  2. What you need to know before starting to use Mometasona Mede
  3. How to use Mometasona Mede
  4. Possible side effects
  5. Storage of Mometasona Mede
  6. Package contents and additional information

1. What Mometasona Mede is and what it is used for

This medicine contains mometasone furoate as the active ingredient, which belongs to the group of topical glucocorticoids and acts as an anti-inflammatory and antipruritic in skin conditions.

Mometasona Mede is indicated for the relief of inflammatory and pruritic manifestations (with itching or scratching) of dermatoses that respond to treatment with glucocorticoids, such as psoriasis (a skin disease characterized by scaling) and atopic dermatitis (a chronic skin condition characterized by the appearance of scaly eruptions, accompanied by itching).

Doctor consultation

Not sure if this medicine is right for you?

Discuss your symptoms and treatment with a doctor online.

2. What you need to know before starting to use Mometasona Mede

Do not use Mometasona Mede

If you are allergic to the active ingredient mometasone furoate, to other corticosteroids, or to any of the other components of this medicine (listed in section 6).

Warnings and precautions

Consult your doctor or pharmacist before starting to use Mometasona Mede.

Be particularly careful with this medicine when treating large body surfaces, when using occlusive dressings, in long-term treatments, or when applying it to the skin of the face or skin folds. Avoid contact with the eyes. In case of accidental contact, wash your eyes with plenty of water.

Contact your doctor if you experience blurred vision or other visual disturbances.

Other medicines and Mometasona Mede

Tell your doctor or pharmacist if you are using or have recently used or may need to use any other medicine, including those purchased without a prescription.

Pregnancy, breastfeeding, and fertility

If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medicine. Mometasona Mede should be avoided in pregnant or breastfeeding women, except on medical prescription.

Driving and using machines

There are no known data to suggest that the product may affect the ability to drive or operate machinery.

Mometasona Mede contains propylene glycol

This medicine contains 300 mg of propylene glycol per gram of cutaneous solution.

Propylene glycol may cause skin irritation.

This medicine contains propylene glycol; do not use on open wounds or large areas of damaged skin (such as burns) without consulting your doctor or pharmacist first.

3. How to use Mometasona Mede

Follow the administration instructions for this medicine exactly as indicated by your doctor or pharmacist. If in doubt, consult your doctor or pharmacist again.

Your doctor will indicate the duration of treatment with this medicine. Do not stop treatment on your own.

If you think the effect of this medicine is too strong or too weak, tell your doctor or pharmacist.

Mometasona Mede is for cutaneous use (applied to the skin or scalp).

The recommended dose is:

Apply a few drops of Mometasona Mede to the affected areas once a day and gently massage until it disappears.

Do not cover or bandage the treated area unless your doctor has indicated it.

If you use more Mometasona Mede than you should:

If you have used more Mometasona Mede than indicated, consult your doctor or pharmacist immediately.

In case of overdose or accidental ingestion, go to a medical center or call the Toxicology Information Service, phone 91 562 04 20, indicating the medicine and the amount used.

If you forget to use Mometasona Mede:

Do not use a double dose to make up for forgotten doses; continue with the usual routine, and if you have forgotten many doses, consult your doctor or pharmacist immediately.

If you stop treatment with Mometasona Mede

Avoid sudden cessation of treatment. As with all highly active steroids, treatment should be discontinued gradually.

If you have any other doubts about using this medicine, ask your doctor or pharmacist.

Medicine questions

Started taking the medicine and have questions?

Discuss your symptoms and treatment with a doctor online.

4. Possible side effects

Like all medicines, this medicine can have side effects, although not everyone gets them.

The following side effects have been reported and are classified according to their frequency:

Very common: (may affect more than 1 in 10 people) Common: (may affect up to 1 in 10 people).

Uncommon: (may affect up to 1 in 100 people).

Rare: (may affect up to 1 in 1,000 people).

Very rare: (may affect up to 1 in 10,000 people)

Frequency not known: (cannot be estimated from the available data)

Disorders of the skin and subcutaneous tissue:

  • Common: burning, folliculitis (inflammation of hair follicles), acneiform reaction (acne), pruritus, and signs of cutaneous atrophy.
  • Uncommon: papules (protuberances), pustules (lesions on the skin surface characterized by being small, inflamed, filled with pus, and similar to a blister), and itching
  • Rare: irritation, hypertrichosis (excessive hair growth in an area), hypopigmentation (reduction in pigment production), perioral dermatitis (red papules around the mouth), allergic contact dermatitis, skin maceration (excessive loss of the protective cornified layer), secondary infection, striae, and miliaria (lesion related to acne in which small, hard, and static white cysts appear)

Endocrine disorders:

  • Rare: adrenocortical suppression (suppression of steroid hormone secretion)

Ocular disorders:

Frequency not known: blurred vision

If you think any of the side effects you are experiencing is serious or if you notice any side effect not mentioned in this leaflet, tell your doctor or pharmacist.

Reporting side effects

If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect not listed in this leaflet. You can also report them directly through the Spanish Medicines and Healthcare Products Agency (AEMPS) website: https://notificaram.es. By reporting side effects, you can help provide more information on the safety of this medicine.

5. Storage of Mometasona Mede

Keep this medicine out of the sight and reach of children.

No special storage conditions are required.

Expiry date: Do not use this medicine after the expiry date stated on the label and carton, after EXP. The expiry date is the last day of the month indicated.

Medicines should not be disposed of via wastewater or household waste. Deposit the containers and medicines you no longer need at the Black medical cross inside a circle with a curved arrow indicating a continuous cyclecollection point in your pharmacy. If in doubt, ask your pharmacist how to dispose of the containers and medicines you no longer need. This will help protect the environment.

6. Package contents and additional information

Composition of Mometasona Mede

The active ingredient is mometasone furoate. Each gram of cutaneous solution contains 1 milligram of mometasone furoate.

The other components are: isopropyl alcohol, propylene glycol (E-1520), hydroxypropyl cellulose, sodium dihydrogen phosphate dihydrate, phosphoric acid, and purified water.

Appearance of the product and package contents

Mometasona Mede 1 mg/g cutaneous solution is a clear and colorless solution.

This medicine is presented in bottles of 30 and 60 ml of cutaneous solution.

Marketing authorization holder and manufacturer:

Laboratorio Reig Jofré S.A.

Gran Capitán, 10

08970 Sant Joan Despí (Barcelona) Spain

Date of the last revision of this leaflet: October 2020

Detailed and updated information on this medicine is available on the website of the Spanish Agency for Medicines and Healthcare Products (AEMPS) http://www.aemps.gob.es/

Online doctors for MOMETASONE MEDE 0.1% CUTANEOUS SOLUTION

Discuss questions about MOMETASONE MEDE 0.1% CUTANEOUS SOLUTION, including use, safety considerations and prescription review, subject to medical assessment and local regulations.

5.0 (3)
Doctor

Tomasz Grzelewski

Dermatology 21 years exp.

Dr Tomasz Grzelewski is an MD, PhD specialist in allergy, paediatrics, general practice and sports medicine, with a clinical focus on dermatology, endocrinology, allergology and sports-related health. He has more than 20 years of clinical experience and completed his medical training at the Medical University of Łódź, where he defended his PhD thesis with distinction. His doctoral research was recognised by the Polish Society of Allergology for its innovative contribution to the field. Throughout his career, he has gained extensive expertise in diagnosing and managing a wide range of allergic and paediatric conditions, including modern allergen desensitisation techniques.

For five years, Dr Grzelewski served as the Head of two paediatric departments in Poland, managing complex clinical cases and leading multidisciplinary teams. He also worked in medical centres in the United Kingdom, gaining experience across both primary care and specialist environments. With over a decade of telemedicine experience, he has provided online consultations across Europe and is valued for his clear, structured and evidence-based medical guidance.

Dr Grzelewski is actively involved in clinical programmes focused on modern anti-allergic therapies. As a Principal Investigator, he leads research projects on sublingual and oral allergen desensitisation, supporting evidence-based progress in allergy treatment for both children and adults.

In addition to his background in allergology and paediatrics, he completed dermatology studies through the Cambridge Education Group (Royal College of Physicians of Ireland) and a Clinical Endocrinology course at Harvard Medical School. This advanced training enhances his ability to manage skin manifestations of allergies, atopic conditions, urticaria, endocrine-related symptoms and complex immunological reactions.

Patients commonly seek his care for:

  • seasonal and perennial allergies
  • allergic rhinitis and chronic nasal symptoms
  • asthma and breathing difficulties
  • food and medication allergies
  • urticaria, atopic dermatitis and skin reactions
  • recurrent infections in children
  • sports-related health questions
  • general family medicine concerns
Dr Tomasz Grzelewski is known for his clear communication style, structured medical approach and ability to explain treatment options in a concise and accessible way. His multidisciplinary background across allergy, paediatrics, dermatology and endocrinology allows him to provide safe, up-to-date and comprehensive care for patients of all ages.
Camera Book a video appointment
€80
5.0 (22)
Doctor

Anna Moret

Dermatology 19 years exp.

Dr. Anna Moret is a board-certified dermatologist and dermatovenereologist. She specialises in adult and pediatric dermatology, venereology, aesthetic skin care, and general medicine. Her consultations are evidence-based and tailored to each patient’s dermatological needs.

Dr. Moret provides expert evaluation and treatment for:

  • Skin conditions such as eczema, acne, rosacea, dermatitis, and psoriasis.
  • Hair and scalp issues including hair loss, dandruff, and seborrheic dermatitis.
  • Pediatric skin problems — from newborns to adolescents.
  • Sexually transmitted infections (STIs) and dermatovenereology.
  • Aesthetic concerns: skin ageing, non-invasive cosmetic treatments.
  • Skin allergies and hypersensitivity reactions.
  • Mole checks, lesion evaluation, and skin cancer screening.
  • Skincare advice and personalised cosmeceutical routines.

Combining dermatology with general medical knowledge, Dr. Moret offers comprehensive care that addresses both skin health and underlying conditions. She also holds certification from the Canadian Board of Aesthetic Medicine, ensuring an internationally aligned approach to aesthetic dermatology.
Camera Book a video appointment
€55

Frequently Asked Questions

Is a prescription required for MOMETASONE MEDE 0.1% CUTANEOUS SOLUTION?
MOMETASONE MEDE 0.1% CUTANEOUS SOLUTION requires a prescription in Spain. You can check with a doctor online whether this medicine may be appropriate for your situation.
What is the active substance in MOMETASONE MEDE 0.1% CUTANEOUS SOLUTION?
The active ingredient in MOMETASONE MEDE 0.1% CUTANEOUS SOLUTION is mometasone. This information helps identify medicines with the same composition but different brand names.
How much does MOMETASONE MEDE 0.1% CUTANEOUS SOLUTION cost in pharmacies?
The average pharmacy price for MOMETASONE MEDE 0.1% CUTANEOUS SOLUTION is around 4.98 EUR. Prices may vary depending on the manufacturer and dosage form.
Who manufactures MOMETASONE MEDE 0.1% CUTANEOUS SOLUTION?
MOMETASONE MEDE 0.1% CUTANEOUS SOLUTION is manufactured by Laboratorio Reig Jofre, S.A.. Pharmacy brands and packaging may differ depending on the distributor.
Which doctors can assess the use of MOMETASONE MEDE 0.1% CUTANEOUS SOLUTION online?
Doctors such as Family doctors, Psychiatrists, Dermatologists, Cardiologists, Endocrinologists, Gastroenterologists, Pulmonologists, Nephrologists, Rheumatologists, Hematologists, Infectious disease physicians, Allergists, Geriatricians, Paediatricians, Oncologists may assess whether MOMETASONE MEDE 0.1% CUTANEOUS SOLUTION is appropriate, depending on your situation and local regulations. You can book an online consultation to discuss your symptoms and possible next steps.
What are the alternatives to MOMETASONE MEDE 0.1% CUTANEOUS SOLUTION?
Other medicines with the same active substance (mometasone) include ELOKOM 1 mg/g CREAM, ELOKOM 1 mg/g OINTMENT, ELOKOM 1 mg/g CUTANEOUS SOLUTION. These may have different brand names or formulations but contain the same therapeutic ingredient. Always consult a doctor before switching or starting a new medicine.
bg-pattern-dark

Stay informed about Oladoctor

News about new services, product updates and useful information for patients.
Follow us on social media